Spurney R F, Coffman T M
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Pharmacol Exp Ther. 1997 Oct;283(1):207-15.
To investigate regulatory domains of the thromboxane A2 (TxA2) receptor, we constructed a truncated form of the mouse TxA2 receptor and expressed it in a mesangial cell line. The mutant receptor lacked 22 amino acids in the C-terminus including four potential phosphorylation sites. Ligand binding of mutant receptors was identical with the wild type. Stimulation with TxA2 agonist induced increases in inositol trisphosphate (IP3) generation and [Ca++]i by both wild-type and mutant receptors. However, the initial increase in IP3 generation by the mutant receptor was only approximately 50% of that seen in the wild type. Exposure of wild-type receptors to TxA2 agonist caused desensitization of IP3 and calcium responses. Pretreatment with TxA2 agonist caused some desensitization of mutant receptors, but the extent of desensitization was reduced compared with the wild type. The protein kinase C inhibitor staurosporine attenuated TxA2-induced desensitization of wild-type receptors, but had little effect on TxA2-induced desensitization of mutant receptors. Pretreatment with low concentrations of the phorbol ester, phorbol 12,13-dibutyrate (100 nM), reduced subsequent responsiveness of wild-type but not mutant TxA2 receptors. In contrast, high-dose phorbol 12,13-dibutyrate (1 microM) produced a similar degree of desensitization of both receptor types. These data suggest that: 1) the C-terminus participates in coupling of the TxA2 receptor to its effector systems; 2) the C-terminus contributes to agonist-specific desensitization of the TxA2 receptor; and 3) protein kinase C-induced desensitization of the TxA2 receptor is complex and depends, in part, on C-terminal domains of the TxA2 receptor.
为了研究血栓素A2(TxA2)受体的调控结构域,我们构建了小鼠TxA2受体的截短形式,并在系膜细胞系中进行表达。突变受体的C末端缺少22个氨基酸,包括四个潜在的磷酸化位点。突变受体的配体结合与野生型相同。TxA2激动剂刺激可使野生型和突变型受体诱导的肌醇三磷酸(IP3)生成增加和细胞内钙离子浓度([Ca++]i)升高。然而,突变受体诱导的IP3生成的初始增加仅约为野生型的50%。野生型受体暴露于TxA2激动剂会导致IP3和钙反应脱敏。用TxA2激动剂预处理会使突变受体产生一定程度的脱敏,但与野生型相比,脱敏程度降低。蛋白激酶C抑制剂星形孢菌素可减弱TxA2诱导的野生型受体脱敏,但对TxA2诱导的突变受体脱敏作用很小。用低浓度佛波酯佛波醇12,13 -二丁酸酯(100 nM)预处理可降低野生型而非突变型TxA2受体的后续反应性。相反,高剂量佛波醇12,13 -二丁酸酯(1 microM)对两种受体类型产生相似程度的脱敏。这些数据表明:1)C末端参与TxA2受体与其效应系统的偶联;2)C末端有助于TxA2受体的激动剂特异性脱敏;3)蛋白激酶C诱导的TxA2受体脱敏是复杂的,部分取决于TxA2受体的C末端结构域。